Felix R. Ehrat

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. See our LinkedIn community guidelines: https://www.idorsia.com/documents/com/policies-charters/idorsia-linkedin-community-guidelines.pdf Idorsia privacy policy: https://www.idorsia.com/system/legal-statements/privacy-policy

Loanboox is the leading European debt financing & management provider. In contrast to conventional brokering, financing and investing through Loanboox is simple, transparent, safe and low cost, benefiting both borrowers and investors alike. Loanbooxs success speaks for itself: Since the Go-live in September 2016, transactions with a volume of 28bn EUR have been closed in 12 countries. 3000 real estate companies, cooperatives, cities, communities, institutional investors and banks use the tools & services provided by Loanboox. Legal notice and contact in Switzerland: Swiss FinTech AG Talacker 50 CH-8001 Zürich info@loanboox.com www.loanboox.com +41 55 220 78 20 UID-number: CHE-283.230.900 --- Contact in Germany: Loanboox GmbH Mainzer Landstraße 33 DE-60329 Frankfurt am Main info@loanboox.de www.loanboox.de +49 69 3486 684 90 Umsatzsteuer-ID: DE312984719

Topadur Pharma AG is a Swiss biopharmaceutical scale-up based in Schlieren, Zurich. The company was founded in 2015 by experienced scientists that combine several years of expertise in R&D Pharma. Topadur’s vision is to improve patients’ quality of life by providing highly effective and safe drugs for unmet medical conditions. Topadur has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases like chronic wounds, skin fibrosis, age-related macular degeneration, colorectal cancer, hair loss and skin aging.

Founded in 1928 in Switzerland, Katadyn is the world’s most trusted Swiss equipment brand for specialists who demand ultimate mission performance when failure is not an option. Katadyn develops water treatment, nutrition and cooking solutions designed to perform in the world’s most demanding conditions. From humanitarian response, disaster relief and professional operations to outdoor and expedition use, Katadyn equips people with water they can trust, food that fuels and gear that performs when it counts. The company’s portfolio includes the brands Katadyn, Trek’n Eat, AlpineAire Foods, Optimus and Spectra Watermakers. Katadyn operates globally with manufacturing facilities in the United States and Europe and employs more than 220 people.

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. See our LinkedIn community guidelines: https://www.idorsia.com/documents/com/policies-charters/idorsia-linkedin-community-guidelines.pdf Idorsia privacy policy: https://www.idorsia.com/system/legal-statements/privacy-policy

Loanboox is the leading European debt financing & management provider. In contrast to conventional brokering, financing and investing through Loanboox is simple, transparent, safe and low cost, benefiting both borrowers and investors alike. Loanbooxs success speaks for itself: Since the Go-live in September 2016, transactions with a volume of 28bn EUR have been closed in 12 countries. 3000 real estate companies, cooperatives, cities, communities, institutional investors and banks use the tools & services provided by Loanboox. Legal notice and contact in Switzerland: Swiss FinTech AG Talacker 50 CH-8001 Zürich info@loanboox.com www.loanboox.com +41 55 220 78 20 UID-number: CHE-283.230.900 --- Contact in Germany: Loanboox GmbH Mainzer Landstraße 33 DE-60329 Frankfurt am Main info@loanboox.de www.loanboox.de +49 69 3486 684 90 Umsatzsteuer-ID: DE312984719

Accenture helps the world’s leading enterprises reinvent by building their digital core and unleashing the power of AI to create value at speed for organizations across industries. Our strategy is to be the reinvention partner of choice for our clients and lead in the safe, widespread adoption of AI, and to be the most client-focused, AI-enabled, great place to work in the world. We bring together the talent of our approximately 786,000 people with proprietary assets and platforms, deep process and industry expertise, and leading ecosystem relationships to deliver end-to-end solutions and measurable outcomes at scale. Through our Reinvention Services, we offer broad expertise across Cybersecurity, Digital Core, Finance, Industry and Enterprise, Song, Supply Chain and Engineering, and Talent, with advanced capabilities in AI and Data, Industry and Process, and Technology. We serve approximately 9,000 clients and generated approximately $70 billion in FY25 revenue. Visit us at accenture.com. This LinkedIn company page is moderated. When engaging with Accenture, we encourage everyone to: - Use common courtesy and be respectful of others. - Create your own original content and avoid content that you know to be fraudulent. - Never repost someone elses copyrighted work, unless you have permission. - Never post personal, identifying, or confidential information. We reserve the right to delete comments or posts we deem to be: - Profane, obscene, inappropriate, offensive, abusive material. - Spam, repeated comments and commercial messages and personal advertisements. - Discriminatory or that contain hateful speech of any kind regarding age, gender, race, religion, nationality, sexual orientation, gender identity or disability. - Threats; personal attacks; abusive, defamatory, derogatory, or inflammatory language; or stalking or harassment of any individual, entity or organization. - False, inaccurate, libelous, or otherwise misleading in any way.